Stately Bio, a Palo Alto, CA based mostly startup creating cell therapies utilizing an ML-powered live-cell imaging platform, raised $12m in seed funding.
The spherical was led by AIX Ventures, with participation from Dimension Capital, Foothill Ventures, Village International, Caffeinated Capital, Mitsui International Funding, BoxOne Ventures, Axial VC, Jeff Dean (Chief Scientist at Google DeepMind), Jeremy Wertheimer (co-founder of ITA Software program), and Tom Berry (co-founder of Carbon Well being).
The corporate intends to make use of the brand new funding to scale its platform know-how and mature its inner pipeline of stem cell-derived therapeutics.
Based in 2022 by Frank Li, CEO, Stately Bio is a biotechnology firm constructing machine studying for regenerative medication. The corporate has developed a computational platform that permits speedy, real-time insights into cell id, high quality, and habits based mostly on live-cell imaging.
The ML-driven imaging platform identifies and screens cells in actual time utilizing solely label-free, live-cell suitable imaging, without having for fluorescent tags or genetic modification. By making use of superior machine studying, the know-how can quantify numerous cell sorts, monitor differentiation progress, optimize protocols, and even forecast manufacturing outcomes, all in actual time with out ever touching or harming the cells. For biopharma firms, these real-time insights translate into sooner course of growth cycles and higher management over high quality and consistency, guaranteeing every run meets the purity and performance wanted for sufferers.
On the invention aspect, the corporate has deployed its know-how platform to enhance the differentiation of stem cells into mature cells of excessive therapeutic worth, beginning with an industry-leading liver cell program. In comparison with the state-of-the-art, Stately Bio’s liver cells present 3x-10x enchancment throughout a panel of metabolic assays of key liver capabilities. The corporate is planning to increase to extra cell sorts and is actively in search of companions to advance the usage of its liver cells for toxicity testing, illness modeling, and therapeutics.
FinSMEs
01/05/2025
